Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for depressive symptoms in PASC
NCT05690503Phase 2Active, not recruiting
- Sponsor
- New York State Psychiatric Institute
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD), sponsored by New York State Psychiatric Institute. Started Mar 2023; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05690503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690503.